Durvalumab Plus Platinum/Etoposide for Extensive-Stage SCLC: Luis Paz-Ares, MD

Because most patients with small-cell lung cancer (SCLC) present with extensive-stage disease—in which the cancer has spread to both lungs or throughout the body—survival rates are poor, and there is a need to develop alternative treatments to improve outcomes. In their study now published in The Lancet, Luis Paz-Ares, MD, and colleagues found that in patients with extensive-stage SCLC (ES-SCLC), the addition of the immunotherapy drug durvalumab to a chemotherapy regimen of platinum/etoposide si...
Continue reading

Finding Solutions in Advanced NSCLC Without Driver Mutations: Jamie E. Chaft, MD

​ Many patients with non-small cell lung cancer (NSCLC) present with advanced disease, which is highly resistant to chemotherapy. Recently, the use of tumor histology and relevant molecular biomarkers in determining optimal treatment strategies has improved outcomes for some patients, yet a number of targeted therapies are not applicable to patients without driver mutations. In this interview with i3 Health, Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center and a...
Continue reading

Nivolumab for Esophageal Cancer: An Interview With Ken Kato, MD, PhD

Results from a phase 3 trial show that nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma (ESCC). In this interview with i3 Health, Ken Kato, MD, PhD, explains the results from this study, as well as rationale for using nivolumab in ESCC, safety considerations, and the study's implications for oncology practice. What is the most challenging aspect of treating patients with advan...
Continue reading

Veliparib Adds Benefits to Ovarian Carcinoma Treatment: An Interview With Robert L. Coleman, MD

High-grade serous ovarian carcinoma is the most malignant form of ovarian cancer, with a high recurrence rate and a low survival rate. While patients are commonly treated with induction chemotherapy consisting of paclitaxel plus carboplatin, there is a need to develop additional first- and second-line therapies to increase survival in patients with this disease. In their study now published in The New England Journal of Medicine, Robert L. Coleman, MD, a Professor in the Department of Gynecologi...
Continue reading

Treating Multiple Myeloma: Challenges, Solutions, and Research Advances With Carol Ann Huff, MD

​ With a five-year survival rate of only 50.7%, multiple myeloma remains difficult to treat. In this interview with i3 Health, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, explores the challenges and research advances of myeloma treatment. She also gives advice on helping patients to find assistance with the prohibitive costs of treatment and on handling the difficulties involved in treating patients at smaller community cancer centers, including patients who ...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.